Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -8.10%35 5-Year RORE % is -26.26 as of Mar. 2026. GuruFocus rates BJDX with a GF Score™ of 35/100. Among 700 Medical Devices & Instruments companies, Bluejay Diagnostics ranks worse than 73.57% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Bluejay Diagnostics's 5-Year RORE % for the quarter that ended in Mar. 2026 was -26.26%.
The industry rank for Bluejay Diagnostics's 5-Year RORE % or its related term are showing as below:
BJDX's 5-Year RORE % is ranked worse than 73.57% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: -4.69
vs BJDX: -26.26
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Bluejay Diagnostics 5-Year RORE % Related Terms
Bluejay Diagnostics 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Bluejay Diagnostics's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJDX vs ALURD, VTAK, AMIX: 5-Year RORE % Comparison
For the Medical Devices subindustry, Bluejay Diagnostics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics 5-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Bluejay Diagnostics (BJDX) has a 5-Year RORE % of -26.26 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Bluejay Diagnostics and its competitors. According to the industry distribution chart, Bluejay Diagnostics ranks #515 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 73.6%.
Is Bluejay Diagnostics' 5-Year RORE % too high?
Bluejay Diagnostics' current 5-Year RORE % is -26.26. Based on the distribution chart, Bluejay Diagnostics ranks #515 out of 700 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bluejay Diagnostics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' 5-Year RORE % compare to ALURD and VTAK?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #515 out of 700 companies for 5-Year RORE %. This places Bluejay Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Bluejay Diagnostics and its competitors. Bluejay Diagnostics's current 5-Year RORE % is -26.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current 5-Year RORE % of -26.26. The current 5-Year RORE % is -26.26. Bluejay Diagnostics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current 5-Year RORE % is -26.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
35GF Score
Get the complete analysis for BJDX
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
